Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $126.65 | Total: $633.25 |
| 1 | 10 | $107.28 | Total: $1,072.80 |
| 1 | 25 | $90.89 | Total: $2,272.25 |
| 1 | 50 | $77.48 | Total: $3,874.00 |
| 1 | 100 | $67.05 | Total: $6,705.00 |
Overview
Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFRHER2.
Chemical Properties
| Molecular Formula | C24H24Br2ClN9O3 |
| Molecular Weight | 681.77 |
| CAS Numbers | 1636180-98-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [Br-].Cn1cnc(c1C[N+](C)(C)CC=CC(=O)Nc1cc2c(Nc3ccc(Cl)c(Br)c3)ncnc2cn1)[N+]([O-])=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Adam V Patterson, et al. Abstract 5358 The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA.